背景:精神分裂症患者的肥胖与抗精神病药物的使用有关,高血压,糖尿病,和血脂异常,这是心血管疾病的关键危险因素。决明子是一种传统的中药,可用于治疗各种眼部疾病。含蒽醌的决明子种子用于降低脂肪和胆固醇的血清水平。
目的:研究决明子粉对超重或肥胖精神分裂症患者体重和血脂的影响。
方法:本研究设计为双盲,随机化,对照试验。将94例超重或肥胖的精神分裂症患者分配到对照组(CG,47例患者)和治疗组(TG,47名患者)接受低剂量决明子粉(每天一次0.3g)和决明子粉(每天一次3.0g),分别,36周。主要结果是体重指数和腰围(WC)的变化。次要结果是血脂的变化,C反应蛋白,白细胞介素-6和糖化血红蛋白.
结果:74例患者完成研究(n=36,CG;n=38,TG)。WC在第二次显著降低(24周,98.63±9.44vs95.80±10.26厘米,p=0.023),第三(36周,98.35±9.46vs95.05±10.07厘米,p=0.002),第四(48周,98.78±9.48vs93.73±10.28厘米,p<0.001)在TG中随访比基线时,但在第四次随访时仅明显低于基线(100.78±13.98vs94.03±9.74cm,p=0.006);在第二秒(101.03±13.62对97.35±8,29厘米,p=0.08)和第三(100.55±13.69vs96.55±8.29厘米,p=0.066)随访。基线和第三次随访之间的血清总胆固醇和低密度脂蛋白水平的差异在TG中大于在CG中(149.68±34.85vs179.08±75.87mg/dL,p=0.033;84.40±28.06vs102.08±34.12mg/dL,分别为p=0.015)。
结论:在超重或肥胖的精神分裂症患者中,口服决明子粉(3.0克)24周和36周减少WC,和口服决明子粉36周可降低总胆固醇和低密度脂蛋白水平,提示决明子粉有助于超重或肥胖精神分裂症患者的治疗。然而,这些结果是初步的,未来的研究应该使用更大的样本量,多个测试中心,和多次给药。
BACKGROUND: Obesity in patients with schizophrenia is related to antipsychotic drug use, hypertension, diabetes, and dyslipidemia, which are critical risk factors for cardiovascular disease.
Cassia seed is a traditional Chinese medicine that can be used to treat various eye disorders. Anthraquinone-containing
Cassia seed were used to lower serum levels of fat and cholesterol.
OBJECTIVE: The effects of
Cassia seed powder on body weight and lipids were investigated in overweight or obese patients with schizophrenia.
METHODS: The present
study was designed as a double-blind, randomized, controlled
trial. Ninety-four patients with schizophrenia who were overweight or obese were assigned to a control group (CG, 47 patients) and treatment group (TG, 47 patients) that received low dose Cassia seed power (0.3 g once daily) and Cassia seed powder (3.0 g once daily), respectively, for 36 weeks. The main outcome was the change in body mass index and waist circumference (WC). The secondary outcome was the change in serum lipids, C-reactive protein, interleukin-6, and glycated hemoglobin.
RESULTS: Seventy-four patients completed the
study (n = 36, CG; n = 38, TG). WC was significantly lower at the second (24 weeks, 98.63 ± 9.44 vs 95.80 ± 10.26 cm, p = 0.023), third (36 weeks, 98.35 ± 9.46 vs 95.05 ± 10.07 cm, p = 0.002), and fourth (48 weeks, 98.78 ± 9.48 vs 93.73 ± 10.28 cm, p < 0.001) follow-ups than at baseline in the TG, but only significantly lower than baseline at the fourth follow-up (100.78 ± 13.98 vs 94.03 ± 9.74 cm, p = 0.006); no significant difference in CG was observed at both the second (101.03 ± 13.62 vs 97.35 ± 8,29 cm, p = 0.08) and third (100.55 ± 13.69 vs 96.55 ± 8.29 cm, p = 0.066) follow-up. The difference in serum total cholesterol and low-density lipoprotein levels between the baseline and the third follow-up was greater in the TG than in the CG (149.68 ± 34.85 vs 179.08 ± 75.87 mg/dL, p = 0.033; 84.40 ± 28.06 vs102.08 ± 34.12 mg/dL, p = 0.015, respectively).
CONCLUSIONS: In patients with schizophrenia who were overweight or obese, oral administration of Cassia seed powder (3.0 g) for 24 weeks and 36 weeks reduced WC, and oral administration of Cassia seed powder for 36 weeks reduced total cholesterol and low-density lipoprotein levels, suggesting that Cassia seed powder aids the management of patients with schizophrenia who are overweight or obese. However, these results are preliminary, and future studies should use larger sample sizes, multiple testing centers, and multiple dosing.